Cecil Nick

Cecil Nick

Cecil Nick

Vice President, Biotechnology

Cecil has been working in regulatory affairs and clinical development for over 30 years with particular expertise in monoclonals and biosimilars; his last 25 years have focused on biological medicines. Cecil’s areas of expertise include: oncology, inflammatory disease, diabetes, growth factors, multiple sclerosis, neurology, antivirals, blood products and vaccines.

Work Experience

From 1987 – 2000 Cecil served as regulatory manager at Novo Nordisk, Ltd. working on the development and registration of biotechnological products and NCEs. His previous experience also includes Farmitalia Carlo Erba, May and Baker, London International Group and Lundbeck. Cecil also has knowledge of health economic assessments, quality assurance, pharmaceutical distribution and clinical research.

Since joining Parexel in February 2001,Cecil has been involved with issues relating to clinical development, regulatory submissions, biosimilars, orphan drugs and training. In the last five years alone, he has worked on scores of clinical development plans connecting the input from pharmacologists, statisticians, therapeutic experts and feasibility analyses to craft development plans which are effective, efficient and achievable within the field of inflammatory disease.

Cecil has been a guest lecturer at Cardiff University M.S. in clinical research and Greenwich University M.S. in pharmaceutical sciences courses, as well as biotech module leader for the TOPRA M.S. course. He is on the editorial panel of SCRIP Clinical Research and has authored many articles.

Cecil’s well-known expertise is recognized in his work on over ten programs, his extensive participation in industry and international meetings and his authorship on such subjects.

Education

Cecil graduated from the University of Cape Town with a bachelor’s degree (Hons) in biochemistry and is a fellow of TOPRA (The Organization of Professionals in Regulatory Affairs).

Connect With Me

We are always available for a conversation.

*